InsidersTradesSigma
Track the XERIS BIOPHARMA HOLDINGS INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €1.5bn. The latest transaction was reported on 12 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: STEVEN PIEPER. All data is openly available.
Analysts rate XERIS BIOPHARMA HOLDINGS INC Strong Buy (bullish), based on 7 analysts. Average price target: US$11.71.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing innovative drug formulations. It specializes in treatments for chronic diseases and medical conditions requiring precise drug administration.